Diabetes News

Endocrinology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Rozenberg S et al. – The results of available clinical studies suggest that breast cancer treatment significantly affect bone turnover, BMD and fracture risk. This is for instance the case for all third–generation aromatase inhibitors.

Related Articles

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers
Journal of Clinical Oncology, 10/29/09    Relevance Score: 74%

Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography Screening
Journal of Clinical Oncology, 11/09/09    Relevance Score: 72%

Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients
Breast Cancer Research and Treatment, 10/27/09    Relevance Score: 72%

Underweight and breast cancer recurrence and death: A report from the Korean breast cancer society
Journal of Clinical Oncology, 10/08/09    Relevance Score: 72%

Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study
Cancer Epidemiology, Biomarkers & Prevention, 10/01/09    Relevance Score: 72%

Today in Bone Metabolism...keeping you current

Low Bone Mass and High Bone Turnover in Postmenopausal Human Immunodeficiency Virus-Infected Women
Journal of Clinical Endocrinology and Metabolism, 12/17/09

Epidemiology of hip fracture in Tucuman, Argentina
Osteoporosis International, 12/17/09

Determinants of serum 25 hydroxyvitamin D levels in a nationwide cohort of blacks and non-Hispanic whites
Cancer Causes and Control, 12/17/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address